Vera Therapeutics says ORIGIN 3 final efficacy data for TRUTAKNA in IgA nephropathy is set for late-breaking ASN Kidney Week 2026 talk

Bitget2026/10/02 13:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vera Therapeutics flagged final efficacy results from the Phase 3 ORIGIN 3 trial of TRUTAKNA in IgA nephropathy.
Results have not been presented yet; they are scheduled for a late-breaking opening plenary talk at ASN Kidney Week 2026 on Oct. 22.
The update is positioned as a confirmatory readout following accelerated approval tied to proteinuria reduction, a key regulatory risk for the franchise.
Separate interim data from the Phase 2 PIONEER basket study in adult IgA nephropathy, primary membranous nephropathy are slated for Oct. 24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020924PRIMZONEFULLFEED9838694) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vera Therapeutics says ORIGIN 3 final efficacy data for TRUTAKNA in IgA nephropathy is set for late-breaking ASN Kidney Week 2026 talk

You may also like

Crypto prices